|Bid||0.0000 x 3200|
|Ask||0.0000 x 4000|
|Day's Range||0.1634 - 0.1928|
|52 Week Range||0.1630 - 4.0800|
|Beta (5Y Monthly)||2.16|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 02, 2022 - Mar 07, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.24|
Calyxt, Inc. (NASDAQ: CLXT) ("Calyxt"), a plant-based synthetic biology company, today announced that its Board of Directors is evaluating potential strategic alternatives to maximize shareholder value. As part of the process, the Board is considering a full range of strategic alternatives, which may include financing alternatives, merger, reverse merger, other business combinations, sale of assets, licensing, or other transactions. Calyxt has retained Canaccord Genuity as its financial advisor
Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced that Michael A. Carr, President and Chief Executive Officer, and Bill Koschak, Chief Financial Officer, will present at the H.C Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022.
Calyxt (CLXT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.